DNA double helix structure was discovered in 1953. Molecular Biology, a new field in science, revealed that two nucleic acids, DNA and RNA, form the structural bases for hereditary and life.
Around the turn of the century, many discoveries related to RNA were made such as “RNA interference” and “Non-coding RNA.” As the role played by RNA in life from birth onwards became clear, research and development in nucleic acid medicine (RNA in particular) began in earnest.
We discovered in our basic research on RNA a phenomenon called “Protein/RNA molecular mimicry.” We then spent about ten years working on the application of this phenomenon in drug discovery. The outcome is that RNA is unexpectedly pliable, binds with various target proteins by “just fitting” and suppresses their action. Focusing on the superior potential of the RNA, I made up my mind to work on research and development in aptamers and founded RIBOMIC Inc.
RIBOMIC’s young researchers are working in tandem with experienced seniors to realize the new aptamer-based medicine that are originated in Japan and the first in the world. We hope that our results will prove to be effective in preventing and treating diseases and lead to further understanding and applications of RNA. And by contributing to the field of drug creation in Japan to catch up with the rest of the world, we believe that we are carrying out our responsibility as a university-originated bioventure company.
At the end, I would like to express my deep gratitude to the people who have supported us to date and ask for continuing support and guidance in the future.
President and CEO, RIBOMIC Inc.
Professor Emeritus, The University of Tokyo